MacroGenics

MGNX · NASDAQ

$3.49+$0.16 (+4.80%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.33

MGNX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 5 analysts

Average $9.52 (+172.8% upside)

Low: $6.06
Now: $3.49
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

MGNX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Aug 17, 2026	Maintains	Buy	$9.00 → $11.00	47%
Barclays	Apr 20, 2026	Maintains	Overweight	$4.00 → $6.00	46%
B. Riley Securities	Apr 10, 2026	Upgrade	Neutral → Buy	$3.00 → $9.00	47%
Barclays	Mar 10, 2026	Maintains	Overweight	$3.00 → $4.00	46%
HC Wainwright & Co.	Nov 3, 2025	Maintains	Neutral	$2.00	41%

The case for and against

Updated Nov 4, 2025

Bull case

Macrogenics Inc. demonstrates a strong positive outlook based on its advanced antibody engineering capabilities, which have facilitated the development of a diverse portfolio of promising product candidates and strategic collaborations with major pharmaceutical and biotechnology firms. The company is currently advancing multiple candidates through clinical development, with MGC026 and lorigerlimab showing promising preclinical and early trial results that could enhance their chances for successful commercialization. Furthermore, the anticipated increase in data flow from earlier-stage programs is likely to attract investor interest, as the current valuation does not adequately reflect the potential for long-term success in the competitive oncology space.

Bear case

Macrogenics Inc reported a GAAP net loss of $41 million, translating to a loss of $(0.65) per share, which exceeded both internal and consensus estimates, indicating financial underperformance. The company's revenue of $13 million fell short of expectations, further exacerbating concerns about its financial viability and ability to sustain operations. Additionally, despite a reduction in operational expenditures, with a 19% year-over-year decrease in GAAP operating expenses and a 26% decline in SG&A spending, the overall financial metrics reflect challenges in generating sufficient revenue to offset substantial losses, contributing to a negative outlook on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.